Category: Regulations
-
Trial Tests Vibrating Mattress to Prevent Infant Apnea
24 November 2015. A mattress that provides occasional mild vibrations was shown in a clinical trial to prevent episodes of interrupted breathing in preterm babies, a condition known as infant apnea. Results of the study testing the device, developed at the Wyss Institute, a biomedical engineering research center at Harvard University, were reported yesterday in…
-
FDA Approves Nasal Spray for Opioid Overdose
20 November 2015. The U.S. Food and Drug Administration this week approved the first formulation of a current drug to treat opioid overdose in nasal spray form. The Narcan nasal spray is made by Adapt Pharma Ltd., a company headquartered in Dublin, Ireland. Opioids work by reducing the intensity of pain signals to the brain, particularly…
-
Trial Testing MRI Depression Treatment with Teens
2 November 2015. A new clinical trial is recruiting adolescents with major depressive disorder to test a therapy using magnetic resonance imaging impulses. The study is testing the NeuroStar TMS Therapy System, already approved for adult patients with major depressive disorder who do not respond to medications. Depression is a widespread condition, which when it becomes…
-
Trial Underway Testing Breast Cancer Surgical Aid
29 October 2015. An early-stage clinical trial is recruiting participants to test a peptide that illuminates tumor cells to be removed in breast cancer surgery. The study is testing the experimental product made by Avelas Biosciences Inc., a biotechnology company in La Jolla, California. The clinical trial is enrolling individuals with primary, non-recurring breast cancer,…
-
Trial Testing Aspirin to Prevent Cancer Recurrence
22 October 2015. A new late-stage clinical trial is underway in the U.K. testing the ability of a daily aspirin to prevent the recurrence of solid tumor cancers. The trial is financed by the advocacy group Cancer Research UK and National Institute for Health Research, a medical research funding agency. The study, led by oncologist…
-
Influenza A Therapy Shown Working in Trial
5 October 2015. A clinical trial testing a synthetic antibody designed to treat influenza A shows the treatment is effective in reducing the spread of flu viruses in humans. Visterra Inc., the therapy’s designer, also received a contract valued as much as $204.5 million from the U.S. Department of Health and Human Services to further…
-
Special: The Next Health Care Disruption
– Sponsored Content – This blog post is part of the ‘Think Further’ series sponsored by Fred Alger Management. For more “Think Further” content, please visit www.thinkfurtheralger.com.” The frustration of the physicians comes through, piercing the structured format of a scientific journal. In July 2015, 118 oncologists at leading medical centers and cancer research institutes…
-
Antibody Shown to Reduce Disability in Multiple Sclerosis
28 September 2015. A late-stage clinical trial shows an engineered antibody can reduce the extent of disability in people with primary progressive multiple sclerosis. The experimental drug, ocrelizumab, is made by Genentech, a biotechnology subsidiary of the pharmaceutical company Roche, in South San Francisco, California. Multiple sclerosis is an autoimmune condition where the immune system attacks…
-
Clinical Trial Underway Testing Cancer Surgery Aid
22 September 2015. A clinical trial is enrolling patients with soft tissue sarcoma to test a synthetic peptide that illuminates cancer cells to make them more easily removed during surgery. The early-stage study is testing the safety of the peptide made by Blaze Bioscience Inc. in Seattle and conducted at Cedars-Sinai Medical Center in Los…
-
Immunotherapy Shown to Clear Some Cervical Lesions
17 September 2015. A clinical trial testing a vaccine designed to clear up cervical lesions or sores before they become cancerous, found women receiving the vaccine eradicated more of these lesions than those receiving a placebo. Results of the intermediate-stage trial, funded by Inovio Pharmaceuticals Inc. that makes the candidate vaccine, appear in today’s issue…